Brief bursts of intense exercise trigger a molecular response linked to a lower risk of cardiovascular and metabolic disease and that are associated with slower biological aging.
Rockefeller's Birsoy and Vinogradova labs teamed up to study how cancer cells rewire their metabolism, and how these changes could be targeted therapeutically.
A new protein-tracing platform reveals how fat and liver cells communicate during fasting, inflammation, and obesity, and links many of those signals to human disease.
Scientists knew that obesity raises the risk of hypertension. Now Paul Cohen's team has uncovered the mechanism—and the enzyme—that explains how fat can stiffen blood vessels and drive blood pressure upward.
New study shows that beige fat suppresses an enzyme that promotes high blood pressure, revealing a new molecular pathway and a potential target for future precision therapies.
Researchers discovered that a crucial first step in the signaling system operates differently than previously thought, an insight that could lead to the next generation of treatments.
Replicative aging of human cells, the result of telomere shortening, is slower at physiological oxygen than at atmospheric oxygen, a difference now shown to be due to low oxygen impairing the ATM kinase response to withered telomeres.
Researchers have learned that the antioxidant glutathione, when operating inside mitochondria, is a key factor enabling tumors to spread from the breast to the lung.
Kivanç Birsoy is uncovering the hidden metabolic pathways that cancer cells exploit. His work could also optimize strategies for using nutrition to improve human health.
New study demonstrates how high-affinity B cells "bank" their best traits instead of rolling the dice and risking deleterious mutations, with implications for better vaccine design.
A collaboration between Rockefeller, MSK, and Weill Cornell answers a longstanding
mystery about the basic biology of the hepatitis B virus, while also proposing a novel therapy.
New findings describe how the enzyme CST is recruited to the end of the telomere, where it maintains telomere length with the help of subtle chemical changes made to the protein POT1.
The end replication problem dictates that telomeres shrink unless telomerase intervenes. But the problem is actually twice as complicated, with telomerase providing only part of the solution.
Birsoy is honored for groundbreaking research uncovering metabolic weaknesses of diseased cells, such as cancer, while shedding light on debilitating mitochondrial diseases and rare genetic disorders.
Researchers have long disagreed over whether ??T cells in the gut promote or discourage tumor growth, but new evidence suggests they have the capacity to do both.
Unlike conventional antiretroviral drugs, treatment with broadly neutralizing antibodies does not rely on vigilant daily dosing and could potentially reduce the body’s reservoir of latent viruses.
Birsoy's groundbreaking research has highlighted key nutrients that cancer cells need to survive, while shedding light on debilitating mitochondrial diseases and rare genetic disorders.
